Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase

Uffe H. Olesen(Rigshospitalet), Maxwell Sehested(National University Hospital), Wieland Kieß(University Hospital Leipzig), Peter Fristrup(Technical University of Denmark), Jun Yoshino(Shimane University Hospital), Shin‐ichiro Imai(Washington University in St. Louis), Annemette Thougaard, Mette Krogh Christensen, Søren Jensby Nielsen(Aarhus University), Peter Buhl Jensen(Rigshospitalet), Antje Garten(University Hospital Leipzig), Jakob Gramstrup Petersen(Rigshospitalet), Fredrik Björkling(University of Copenhagen)
BMC Cancer
December 1, 2010
Cited by 52


Related Papers